A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...
A data analysis found the inhaled therapy Tyvaso outperformed a placebo at preserving lung function in people with IPF in a ...
Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...
Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...
The actor tells AARP about her mom’s struggle with pulmonary fibrosis and the warning signs that might help others get an earlier diagnosis ...
DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
UNAGI, a deep generative neural network, tracks IPF progression and identifies potential therapies by analyzing cell types and disease-related genes. The model autonomously learns and refines itself, ...
When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...
Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results